Yoshiko Urata

576 total citations
34 papers, 322 citations indexed

About

Yoshiko Urata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Yoshiko Urata has authored 34 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 3 papers in Surgery. Recurrent topics in Yoshiko Urata's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Yoshiko Urata is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Colorectal Cancer Treatments and Studies (13 papers). Yoshiko Urata collaborates with scholars based in Japan, United States and Italy. Yoshiko Urata's co-authors include Shunichi Negoro, Miyako Satouchi, Yoshihiro Hattori, Nobuyuki Katakami, Akito Hata, Motoko Tachihara, Satoshi Morita, Fumio Imamura, Yuko Kono and Soichiro Yokota and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Yoshiko Urata

34 papers receiving 317 citations

Peers

Countries citing papers authored by Yoshiko Urata

Since Specialization

Citations

This map shows the geographic impact of Yoshiko Urata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiko Urata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiko Urata more than expected).

Fields of papers citing papers by Yoshiko Urata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiko Urata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiko Urata. The network helps show where Yoshiko Urata may publish in the future.

Co-authorship network of co-authors of Yoshiko Urata

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiko Urata. A scholar is included among the top collaborators of Yoshiko Urata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiko Urata. Yoshiko Urata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS) 2022 ·International Journal of Clinical Oncology ·(unknown), Toshihide Yokoyama, Satoshi Morita, Tatsuro Okamoto, Yoshiko Urata, Yoshihiro Hattori, Yasuo Iwamoto, Yuki Sato, Norihiko Ikeda, Toshiaki Takahashi, Haruko Daga, Tetsuya Oguri, Yasuhito Fujisaka, Kazumi Nishino, Shunichi Sugawara, Toshiyuki Kozuki, Masahide Oki, Nobuyuki Yamamoto, Kazuhiko Nakagawa	1
2	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR) 2021 ·Translational Lung Cancer Research ·Hibiki Udagawa, Eri Sugiyama, Toshiyuki Harada, Shinji Atagi, Ryo Koyama, Satoshi Watanabe, Yukiko Nakamura, Daijiro Harada, Osamu Hataji, Fumihiro Tanaka, Hiroshi Kida, Miyako Satouchi, Ken Maeno, Akira Inoue, Kiyotaka Yoh, Yuki Yamane, Yoshiko Urata, Hiroshige Yoshioka, Takeharu Yamanaka, Kōichi Goto	2
3	The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients 2020 ·Respiratory Investigation ·Miho Tanaka, Yoshihiro Hattori, Tatsuya Ishii, (unknown), (unknown), (unknown), Yuko Kono, Yoshiko Urata, Miyako Satouchi	4
4	A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer 2020 ·BMC Cancer ·Yoshihiro Hattori, Yuko Kono, (unknown), Takako Inoue, Yoshiko Urata, (unknown), (unknown), Toru Kumagai, Kazumi Nishino, Ryuji Uozumi, Satoshi Morita, Shunichi Negoro, Fumio Imamura, Miyako Satouchi	7
5	A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116) 2019 ·Annals of Oncology ·Akito Hata, Miyako Satouchi, Satoshi Morita, Yosuke Ota, Yoshiko Urata, (unknown), (unknown), Hiroshi Mayahara, Masaki Kokubo, Yuki Akazawa, Takeshi Uenami, Motohiro Tamiya, Kei Kunimasa, Kyosuke Nakata, Daijiro Harada, Akira Nakamura, (unknown), Nobuyuki Katakami, Shunichi Negoro	1
6	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations 2018 ·Lung Cancer ·Ken Uchibori, Miyako Satouchi, Naoko Sueoka‐Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami, (unknown), Tomonori Hirashima, Kentaro Iwanaga, Masahide Mori, Keisuke Aoe, Satoshi Morita, Shunichi Negoro	13
7	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316) 2018 ·BMC Cancer ·Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, Yuki Akazawa, Takeshi Uenami, Yoshiko Urata, Yoshihiro Hattori, Akito Hata, Nobuyuki Katakami, Soichiro Yokota	32
8	Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study 2016 ·Respiratory Investigation ·(unknown), Yoshihiro Hattori, Tatsunori Kiriu, (unknown), (unknown), Masatsugu Yamamoto, Yoshiko Urata, (unknown), Kayoko Tsujino, Toshinori Soejima, Shunichi Negoro, Miyako Satouchi	3
9	A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. 2016 ·Journal of Clinical Oncology ·Takashi Seto, Kiyotaka Yoh, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Kaname Nosaki, Yoshiko Urata, Seiji Niho, Atsushi Horiike, Takashi Kohno, Shingo Matsumoto, Shogo Nomura, (unknown), Akihiro Sato, Yuichiro Ohe, Takeharu Yamanaka, Atsushi Ohtsu, Kōichi Goto	12
10	A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110) 2015 ·Lung Cancer ·Kazumi Nishino, Fumio Imamura, Toru Kumagai, Nobuyuki Katakami, Akito Hata, Chiyuki Okuda, Yoshiko Urata, (unknown), Motoko Tachihara, (unknown), Takashi Nishimura, Toshihiko Kaneda, Miyako Satouchi, Satoshi Morita, Shunichi Negoro	15
11	A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002) 2015 ·Cancer Chemotherapy and Pharmacology ·Akito Hata, Nobuyuki Katakami, Shiro Fujita, Shigeki Nanjo, Jumpei Takeshita, Kosuke Tanaka, Toshihiko Kaneda, Akihiro Nishiyama, Takashi Nishimura, Atsushi Nakagawa, Kojiro Otsuka, Satoshi Morita, Yoshiko Urata, Shunichi Negoro	6
12	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109) 2014 ·Lung Cancer ·Yoshihiro Hattori, Miyako Satouchi, (unknown), Yoshiko Urata, Tsutomu Yoneda, Masahide Mori, Takashi Nishimura, (unknown), Toru Kumagai, Fumio Imamura, Shiro Fujita, Reiko Kaji, Akito Hata, Motoko Tachihara, Satoshi Morita, Shunichi Negoro	16
13	Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. 2014 ·Journal of Clinical Oncology ·Nobuyuki Katakami, Satoshi Morita, Hiroshige Yoshioka, Takashi Seto, Yoshiko Urata, Miyako Satouchi, Yasuo Iwamoto, Kojiro Otsuka, Norihiko Ikeda, Toshiaki Takahashi, Haruko Daga, Tetsuya Oguri, Isao Goto, Junji Uchida, Shunichi Sugawara, Chiyoe Kitagawa, (unknown), (unknown), Kazuhiko Nakagawa, Yoichi Nakanishi, (unknown)	8
14	A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001) 2013 ·Cancer Chemotherapy and Pharmacology ·Yoshihiro Hattori, Miyako Satouchi, Nobuyuki Katakami, Shiro Fujita, Reiko Kaji, Akito Hata, Yoshiko Urata, (unknown), Junji Uchida, Keisuke Tomii, Satoshi Morita, Shunichi Negoro	2
15	Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer 2013 ·Cancer ·Yoshiko Urata, Isamu Okamoto, Masayuki Takeda, Yoshihiro Hattori, (unknown), (unknown), Takayasu Kurata, Hiroyasu Kaneda, Masaki Miyazaki, Masaaki Terashima, Kaoru Tanaka, Satoshi Morita, Kazuhiko Nakagawa, Shunichi Negoro, Miyako Satouchi	9
16	Randomized Phase II Study of Two Different Schedules of Gemcitabine and Oral S-1 in Chemo-naïve Patients with Advanced Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Miyako Satouchi, Yoshikazu Kotani, Nobuyuki Katakami, (unknown), Yoshiko Urata, (unknown), Yasuhiro Funada, Akito Hata, Masahiko Ando, Shunichi Negoro	10
17	P3-151: EGFR mutation–based phase II multicenter trial of gefitinib in patients with advanced non–small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG0403) 2007 ·Journal of Thoracic Oncology ·Yoshiko Urata, Takashi Seto, Isamu Okamoto, Tatsuhiko Kashii, Tomonori Hirashima, S. Kudoh, Noriyuki Ebi, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka	2
18	Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug 2007 ·Medical Oncology ·Yoshiko Urata, Shunichi Negoro, Miyako Satouchi, Takayasu Kurata, (unknown), (unknown), Yoshiki Takada	1
19	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib 2007 ·British Journal of Cancer ·Miyako Satouchi, Shunichi Negoro, Yasuhiro Funada, Yoshiko Urata, (unknown), Shin‐ichiro Yoshimura, Yoshikazu Kotani, Takahiko Sakuma, Hiroshi Watanabe, Shuji Adachi, Y Takada, Yasushi Yatabe, Tetsuya Mitsudomi	35
20	[Pulmonary thromboembolism associated with familial protein C deficiency type I]. 2003 ·PubMed ·(unknown), Yoshihiro Nishimura, Yasuhiro Funada, (unknown), Kazuyuki Kobayashi, Yoshiko Urata, (unknown), Teruaki Nishiuma, Miyako Satouchi, Mitsuhiro Yokoyama	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact